Ingelheim, Germany 14 November 2014 – Keeping with the tradition of raising awareness amongst employees around disease areas and supporting programmes that have a positive global impact, Boehringer Ingelheim organized the first joint run between Metabolism and Cardiovascular therapeutic areas to support both the World Stroke Organisation (WSO) and the “Life for a Child Programme” of the International Diabetes Federation (IDF). New data about a diabetes drug from Boehringer Ingelheim could help the firm fetch a higher price for the medicine in Germany and also give patients more cause for hope. JARDIANCE is a member of the sodium glucose co-transporter-2 (SGLT2) inhibitor class of compounds. Empagliflozin is part of a class of drugs being investigated for the reduction of blood glucose levels in adults with T2D. IPF has no known cause, is often misdiagnosed, there are few treatments and no cure. Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor discovered by Boehringer Ingelheim and being developed as an oral once-daily tablet for the treatment of Type 2 diabetes. Find out more about the alliance at www.boehringer-ingelheim.com or www.lilly.com.
About Boehringer Ingelheim The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. This summer, AdhereTech, which is based in New York, NY, will begin a trial with The Walter Reed Army Medical Center to test its full-service solution for type 2 diabetes patients. Comparative effectiveness studies examining the effects of different pharmacological treatment strategies on glycemic control, lipids, blood pressure, and other cardiovascular risk factors in patients with diabetes at various stages of CKD, up to and including ESRD/dialysis. TRADJENTA is a tablet that can be taken with or without food. Boehringer Ingelheim The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Steven Edelman, USA, Dr. For more information, visit www.TheDiabetesRegistry.org.
Depending on geographies, the companies either co-promote or separately promote the respective molecules each contributed to the alliance. Initial measurements performed on tissue have provided an accuracy of nearly 70% compared to reference measurements. The team is working to improve this accuracy and developing a portable prototype device for wide-scale use and commercialization. People with diabetes are two to four times more likely to develop CV disease than people without diabetes. Team SmartSense, third place winners of $5,000; members Dr. Over a median of 3.1 years, JARDIANCE significantly reduced the risk of CV death, non-fatal heart attack or non-fatal stroke by 14 percent versus placebo. Sadawana, Dr.
Rohit Srivastava, and Dr. Yogesh Patil. SmartSense is a multianalyte sensing device for diabetic ketoacidosis (DKA). In particular, miRNA-192 has been shown to be induced in glomerular mesangial cells in experimental diabetic nephropathy where it promotes collagen production  and mediates TGF-β/Smad3-induced tubulo-interstitial fibrosis . According to team members, it is designed to reduce the pain and economic burden faced by patients with DKA. The developing team of SmartSense is based at the Indian Institute of Technology Bombay. Team EndoGoal; members Dr.
Jennifer Shine Dyer, (Twitter’s @EndoGoddess), and Jeff Harper, DuetHealth. By joining forces, the companies demonstrate commitment in the care of patients with diabetes and stand together to focus on patient needs. Through research and collaboration, a broad and growing product portfolio and a continued determination to provide real solutions—from medicines to support programs and more—we strive to make life better for all those affected by diabetes around the world. Revenue comes from users’ family-and-friend ‘sponsors.’ For more information about the Columbus, Ohio-based initiative, visit www.endogoal.com. It is unknown if JARDIANCE passes into your breast milk. Overall, more than 100 teams representing 20 countries around the globe submitted diabetes innovations for the Healthcare Innovation World Cup, which awarded a total $75,000 in prizes to semifinalists and finalists. For more information about the competition and judges, visit www.healthcareinnovationworldcup.com.
About Boehringer Ingelheim The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 140 affiliates and more than 46,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine. Social responsibility is a central element of Boehringer Ingelheim’s culture. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim’s endeavours.